Pfizer gets fresh cancer drug rejection from NICE
LONDON (Reuters) - Pfizer's new chronic myeloid leukaemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said on Tuesday.
The latest draft guidance from the National Institute for Health and Clinical Excellence (NICE), which is subject consultation, follows two earlier rebuffs for new cancer drugs developed by Pfizer this year.
(Reporting by Ben Hirschler; Editing by David Cowell)
- Tweet this
- Share this
- Digg this
- Israel warns of long Gaza war as Palestinian fighters cross border |
- Court orders Russia to pay $50 billion for seizing Yukos assets |
- Nigeria isolates hospital in Lagos as Obama briefed on Ebola outbreak
- West agrees wider Russia sanctions as Kiev says forces near crash site |
- Russia, Germany up diplomatic battle over Ukraine sanctions